Pfizer-linked studies registered: rimegepant chemo trial, HIBA respiratory virus review
Two Pfizer-collaborated studies posted this week, a Phase II head and neck cancer trial in China and a retrospective Argentine cohort study on RSV, flu, and COVID-19 outcomes.
Two new registry entries this week involve Pfizer as a collaborator, with other institutions as lead sponsors.
- Shanghai Zhongshan Hospital registered a Phase II randomized trial (NCT07812467) testing rimegepant added to standard neoadjuvant chemoimmunotherapy in oral and oropharyngeal squamous cell carcinoma. The trial is structured with an initial safety run-in stage involving 20 participants, followed by a randomized controlled stage involving 200 participants1, and the primary outcome is the major pathological response rate, defined as 10% or less residual viable tumor in the surgical specimen1. Status is not yet recruiting, with an estimated start of 2026-10-01.
- Hospital Italiano de Buenos Aires registered a retrospective cohort study (NCT07816471), sponsored with Pfizer as collaborator, examining outcomes in severely immunosuppressed adults diagnosed with RSV, influenza, or SARS-CoV-2. The study draws on medical records from a hospital network in Buenos Aires, Argentina, spanning two periods, November 2011 to March 2020 and May 2022 to December 20252. Status is active not recruiting, with primary completion listed as 2025-12-31.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.